Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Adult
Brain
/ diagnostic imaging
Carcinoma, Renal Cell
/ diagnostic imaging
Gallium Radioisotopes
Humans
Kidney Neoplasms
/ diagnostic imaging
Male
Niacinamide
/ analogs & derivatives
Oligopeptides
Positron Emission Tomography Computed Tomography
Prospective Studies
Prostatic Neoplasms
/ pathology
Radiopharmaceuticals
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
11
6
2022
Statut:
ppublish
Résumé
18F-PSMA PET/CT is an emerging standard of care in staging prostate cancer, evaluating biochemical recurrence and response to therapy. Despite the nomenclature, PSMA expression is also documented at the tumor-associated neovasculature of other malignant solid tumors including renal cell carcinoma. We report a case of 44-year-old man known to have renal cell carcinoma who underwent 18F-PSMA and 18F-FDG PET/CT for restaging after radical nephrectomy. A well-defined solitary cerebellar lesion with marked PSMA expression and equivocal FDG uptake was noted. MRI brain confirmed a matching cerebellar metastatic lesion. 18F-PSMA expression in the metastatic RCC raises a prospective guide to futuristic theragnostic uses.
Identifiants
pubmed: 35675136
doi: 10.1097/RLU.0000000000004162
pii: 00003072-202207000-00009
doi:
Substances chimiques
Gallium Radioisotopes
0
Oligopeptides
0
PSMA-1007
0
Radiopharmaceuticals
0
Niacinamide
25X51I8RD4
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
627-628Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Pierorazio PM, Johnson MH, Patel HD, et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol . 2016;196:989–999.
Wyler L, Napoli CU, Ingold B, et al. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. Br J Cancer . 2014;110:686–694.
Dudek AZ, Raza A, Chi M, et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer . 2013;11:155–160.
Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol . 2009;181:518–523.
Ma H, Shen G, Liu B, et al. Diagnostic performance of 18 F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun . 2017;38:156–163.
Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med . 1998;39:778–785.
Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res . 1999;59:3192–3198.
Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol . 2006;26:5310–5324.
Pozzessere C, Bassanelli M, Ceribelli A, et al. Renal cell carcinoma: the oncologist asks, can PSMA PET/CT answer? Curr Urol Rep . 2019;20:68.
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med . 2017;376:354–366.